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Abstract

The syntheses of racemic and homochiral [4.4]-spirolactams, starting from L-proline,
in good yields are described. Reduction of the lactam carbonyl group of spirolactams,
containing chiral substituents on the lactam nitrogen, with lithium aluminium hydride,
gives a series of homochiral [4.4]-spirodiamines. The crystal structure of one of these
spirodiamines on complexation with zinc chloride was obtained. Interestingly it
showed a hydrogen-bonded dimeric structure, where the monomers are
diastereoisomeric diamines.
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Introduction

Diamines, especially vicinal diamines, are of interest because of their ability to
strongly bind metal ions leading to Lewis acid complexes, which have found uses as
catalysts in a wide range of organic syntheses.1 Many of the well known diamines,
such as ethylenediamine (1, Figure 1), are acyclic and are very flexible in nature. The
introduction of constraints into such structures is a well studied method for reducing

this conformational flexibility giving molecules with a more defined 3-D structure
[e.g., trans-1,2-diaminocyclohexane (2)2 is a constrained version of ethylenediamine].
In some cases this has been used in biologically active molecules to either increase the
affinity of the molecule for its target (cyclic versus acyclic peptides),3 or to make the
molecules more metabolically stable, which can lead to improved bioavailability.4
The naturally occurring polycyclic diamine (-)-sparteine (3) has found use as a chiral
ligand in a number of applications in asymmetric synthesis.5 Another method of
constraint which has been used is to introduce a spiro fusion of two rings which forces
the nitrogen atoms into a mutually orthogonal relationship (4, Figure 1).

There are currently a large number of methods for the synthesis of spirocyclic
compounds and they can also be easily formed in a stereocontrolled manner.6
Freidinger was the first to incorporate a lactam constraint in the backbone of a peptide
in order to rigidify the peptide tertiary structure into a more defined conformation.7
One of the most common methods for the synthesis of lactams is the cyclisation of an
amino group (primary or secondary) onto a carboxylic ester, with concomitant loss of
an alcohol. The overall efficiency of the cyclisation is dependent on the size of the
ring being formed, the nature of the amino substitutent in the case of a secondary
amine, any substituents on the resulting ring and the structure of the alkyl moiety of
the ester group. Many of the reactions take place spontaneously at ambient
temperature, while others require heating in a suitable solvent.8

L-Proline-derived

spirolactams have in particular been studied for their use in

constraining peptides with L-proline residues to mimic the -turn, a very important
component of peptide secondary structure. Depending on their final use spirolactams
are synthesised either as racemic mixtures or as single enantiomers. In most cases
these syntheses start from L-proline which must then be alkylated in the -position.
Full control of the stereochemistry can easily be achieved using Seebach’s “SelfReproduction of Chirality” methodology,9 whereas the racemic compounds simply
require alkylation of the enolate of a suitably protected proline molecule which, after
a series of further functional group manipulations, gives cyclisation precursors.
A number of different strategies have also been used for the critical final cyclisation
step to form the spirobicyclic lactam ring. These include (i) intramolecular amide

coupling, with a coupling agent (e.g. DCC or EDC), of tethered secondary amines
with the deprotected proline carboxylic acid group;10 (ii) cyclisation of proline
carboxylic amides onto a primary alcohol under Mitsunobu conditions;11 and (iii)
thermal cyclisation of a tethered secondary amine onto a proline carboxylic ester in
DMF at 70 oC, although the yield of the latter reaction was very low (27%), with only
one diastereoisomer cyclising and the side chain carboxylic acid subsequently being
converted to the methyl ester by treatment with diazomethane (Figure 2).12

Results and Discussion

As part of a programme of research to synthesise both racemic and homochiral
spirocycles, the synthesis of proline-derived [4.4]-spirolactams13,15

and their

conversion to spirodiamines was of interest.

The variety of different cyclisation methods used, along with their wide ranging
yields, prompted us to study one of the methods, the thermal cyclisation reaction, in
more detail in order to investigate whether it was a viable method for the synthesis of
a range of proline-derived [4.4]-spirolactams. This necessitated the synthesis of
secondary amines for subsequent cyclisation onto a carboxylic ester (Scheme 1).13

The required secondary amines (9a-c) would be obtained by reductive amination of
the racemic aldehyde 8, so the efficient synthesis of this aldehyde was critical to the
overall success of this method, as a generalised route to spirolactams. 8 was prepared
in 4 steps from L-proline by Boc protection of the nitrogen of the methyl ester of Lproline, which was obtained quantitatively from L-proline by treatment with SOCl2 in
methanol. The -allyl group was efficiently introduced in 80% yield.14 Oxidative
cleavage of the alkene using OsO4/NaIO4 gave the aldehyde 8 in a 74% yield.10e It
was necessary to efficiently purify the aldehyde by column chromatography to free it
from any traces of osmium by-products, as failure to do so led to major reductions in
the yield of the subsequent reductive amination and cyclisation reactions, with a large
amount of decomposition occurring. Reductive amination of 8 with allyl amine, gave
the required secondary amine spirolactam precursor 9a. Following the method of
Johnson11a, thermal cyclcisation of 9a in DMF at 70 oC gave the spirolactam 10a in a

99% yield, though the work-up was lengthy. Cyclisation in refluxing toluene gave 10a
in a 66% yield, with a simpler work-up procedure. When benzylamine was used in
place of allyl amine, using the same reaction cyclisation conditions, the N-benzyl
substituted spirolactam (10a) was obtained in a higher yield of 75%.
Extension of this methodology using chiral -substituted amines would give pairs of
diastereoisomeric spirolactams.15 Reductive amination of aldehyde 8 with either (R)or (S)--methylbenzylamine gave spirolactams 11a & 11b (Scheme 2). Prolonged
stirring of solutions of these compounds in refluxing toluene gave no indication of
any cyclisation. In a similar cyclisation reaction of a secondary amine, where alanine
methyl ester was used in the reductive amination step, Auberson et al. were able to
successfully achieve cyclisation in yields of >90%, by stirring at reflux temperature in
xylenes for 2 hours.16 Stirring solutions of amino esters 11a or 11b in refluxing
xylenes, even for extended periods of time, gave no indication of any cyclisation
reaction occurring.

Treatment of toluene solutions of 11a or 11b with sodium amide (50% solution in
toluene) at reflux temperature gave the desired spirolactams 12a-d (as pairs of
diastereoisomers in 1:1 ratios), isolated in yields of 30% and 51%, from aldehyde 8.
HPLC analysis of each diastereoisomer showed a high degree of purity (all greater
than 98.8% pure). The only impurity identified, in each case, was the
diastereoisomeric product produced in the reaction.

It was not possible to obtain crystals suitable for X-ray analysis of any of the four
diastereoisomers 12a-d. Although the stereochemistry of the -methyl benzyl
substituent was known from the choice of the starting homochiral amine the absolute
stereochemistry of the spiro centre in each case was not. Molecular modelling17 was
used to give minimised energy conformations of the SR and RR diastereoisomeric pair
(12a & 12b). It was immediately evident from the minimised structures (Figure 3)
that in the SR diastereoisomer the hydrogens of the Boc protecting group and the meta
hydrogens of the phenyl group were close in space (closest distance of 2.67 Å),
whereas in the RR isomer the Boc and phenyl groups were a large distance apart. It
was therefore expected that NOE NMR experiments would be able to distinguish

between the two diastereoisomers. Irradiation of the signal for the hydrogens of the
Boc group of the diastereoisomer assigned as SR showed an NOE to the phenyl
hydrogens, whilst no similar NOE was observed in the case of the RR
diastereoisomer, though this is not conclusive proof of the absolute stereochemistry of
the spiro centre.

The homochiral diamines derived from the spirolactams 12a-d were obtained when
the N-Boc protecting group was cleanly removed from each spirolactam to give the
free amino spirolactams 13a-d, and the reduction of the lactams was then examined.
The optimal conditions found for successful reduction was the use of 20 molar
equivalents of lithium aluminium hydride in THF (Scheme 3), which gave the
diamines 14a-d in acceptable isolated yields (43-56%).

One of our interests is in the use of these diamines as ligands for metal ions, thus
giving chiral complexes which may have potential as novel chiral catalysts in
asymmetric transformations. The first step was to examine whether the amines bound
to a metal ion. No complexation was observed when ethanolic solutions of the amines
were treated with copper(II) acetate. Zinc(II) was then chosen as it is diamagnetic,
making studies of complexation also possible by NMR spectroscopy. When ethanolic
solutions of amines 14a-d were refluxed with 1.5 molar equivalents of ZnCl2 and the
solutions were left standing at room temperature, the solutions containing amines 14a
and 14b each gave one small single crystal (15a and 15b) suitable for X-ray analysis.
The surprise result from these studies was that the X-ray crystal structures of the zinc
complexes 15a and 15b were identical (Figure 3).

Close examination of the X-ray structures shows that a 1:1 dimeric complex had
formed where each spirodiamine accommodates one zinc metal. The asymmetric unit
of the crystal contains two independent molecules linked into a hydrogen-bonded
dimer. Each zinc atom occupies a pseudo-tetrahedral geometry, where it is complexed
to the two nitrogens of the spirocycle and to two chlorine atoms. The N-Zn-N angle is
84.4(2)o in both molecules of the dimer, and the Cl-Zn-Cl angle is 120.71(7) o in one
molecule while it is 119.11(7)o in the other. The dimer is then formed by two
intermolecular hydrogen bonds via one of the chlorine atoms and an amine N-H. The
nitrogen to chlorine distances for the two hydrogen bonds are 3.355(6) and 3.372(6)

Å. The important bond lengths and angles are shown in Table 1. The formation of a
dimer may not in itself unusual, but the most intriguing aspect of the crystal structure
is that the two spirodiamines that make up the dimer are diastereoisomeric. This result
was certainly not anticipated as purification of each precursor amine (14a-d) was
carried out very carefully. HPLC analysis showed that there was only a very small
amount of the corresponding disatereoisomer present in the “purified” amines. In the
case of 14a it was shown to be 98.7% pure with 1.2% of 14b being present. Therefore
on complexation with zinc chloride the vast majority of complexed diamine 14a
remained in solution with only a small amount crystallising out with the opposite
diastereoisomeric diamine “impurity” 14b. Also by HPLC analysis amine 14b was
found to be 99.3% pure, contaminated with only 0.7% of the diasteresoisomer 14a.
Again on complexation with zinc chloride the same result was obtained as before.

Thus the ability of the chiral spirodiamines to complex a selected metal ion has been
demonstrated. Mukaiyama has studied the asymmetric catalysis of the aldol reaction
(Mukaiyama aldol) using diamines derived from L-proline, which are complexed to
tin(II) triflate, as asymmetric catalysts (Figure 4).18 Using molecular modelling,17
when the proline-derived diamine 16 was bound to zinc chloride and was minimised,
the N-N distance was calculated to be 2.77 Å. From the crystal structure of complex
15a it is observed that the N-N distances are 2.797 Å and 2.798 Å. Thus these
distances compare very favourably with the calculated value for the Mukaiyama
ligand 16, above. This leads us to believe that the spirodiamines 14a-d have the
potential to be used as ligands for Sn2+, with the resulting complexes being used as
catalysts in the asymmetric Mukaiyama aldol reaction. It is also envisaged that the
spirodiamines will complex other metal ions, and thus have applications in metal
catalysed asymmetric synthetic reactions. It is also envisaged that the homochiral
spirolactams 13a-d will have applications as novel organocatalysts. All of these
studies are currently being undertaken.

Conclusions.

In conclusion, a series of homochiral spirolactams derived from L-proline have been
prepared. These spirolactams were reduced to spirodiamines using lithium aluminium
hydride as reductant, and the diamines formed complexes with zinc chloride. The X-

ray crystal structure of one of these complexes showed an unusual dimeric form
where the two spirodiamines present were diastereoisomeric. The properties of these
spirodiamines are currently being further elucidated and their potential as ligands for
metals to act as catalysts in asymmetric synthesis is currently being undertaken. The
results of these studies will be reported in due course.

Experimental.

Allyl bromide was purified by passing it through a plug of activity III basic alumina.
TLC was performed on Merck silica gel 60F254 plates and column chromatography
was performed on Aldrich silica gel, 70-230 mesh, 60Å. 1H and 13C NMR ( ppm; J
Hz) spectra were recorded on a Jeol JNM-LA300 FT-NMR spectrometer using CDCl3
solutions with Me4Si as internal reference, unless otherwise indicated, with
resolutions of 0.18 Hz and 0.01 ppm, respectively. CHCl3 was used to remove last
traces of ethyl acetate from some samples. The last trace of CHCl3 persisted even
after prolonged heating in vacuo and in these cases was visible in NMR spectra and
microanalysis. Infrared spectra (cm-1) were recorded as KBr discs or liquid films
between NaCl plates using a Nicolet Impact 410 FT-IR. Melting points were obtained
on a Bibby Stuart Scientific SMP1 melting point apparatus and are uncorrected.
Microanalyses were carried out at the Microanalytical Laboratory of University
College Dublin. Mass spectra were obtained in the Centre for Synthesis and Chemical
Biology, School of Chemistry and Chemical Biology, University College Dublin. Xray crystal structures were obtained in the Chemistry Department, Loughborough
University, Loughborough, UK. HPLC analysis were carried out using methods on a
Shimadzu HPLC system Class-VP, incorporating a LC-10AD pump, SPD-M10AVP
Diode Array Detector, Auto-injector SIJ-10A with a system controller SCL-10A VP.
Polarimetry was carried out at Dublin City University (DCU), using a Perkin-Elmer
343 with cell path-length of 100 mm at 20 oC.
N-Boc-L-proline methyl ester (6).14
6 was prepared from L-proline by the method of Confalone.14 Microanalysis: Found
C, 57.51; H, 8.60; N, 5.88. Calculated for C11H19NO4: C, 57.60; H, 8.34; N, 6.10.

-Allyl N-Boc-proline methyl ester (7).14
7 was prepared from 6 by the method of Confalone,14 except a 1M solution of
LiHMDS in tetrahydrofuran, instead of hexane, was used as the base. Microanalysis:
Found C, 62.29; H, 8.80; N, 4.95. Calculated for C14H23NO4: C, 62.43; H, 8.61; N,
5.20.
()--Formylmethyl N-Boc-proline methyl ester (8).10e
8 was prepared from 7 by the method of Johnson.10e Microanalysis: Found C, 53.59;
H, 7.60; N, 4.22. Calculated for C14H23NO4 (0.33 CHCl3): C, 53.43; H, 7.40; N, 4.67.
7-Allyl-6-oxo-1,7-diazaspiro[4.4]nonane-1-carboxylic acid tert-butyl ester
(10a) Method A: To a stirred solution of 8 (0.10 g, 0.35 mmol) in ethanol (3 ml)
under nitrogen, was added dropwise allyl amine (0.030 ml, 0.35 mmol), over 10 min
at ambient temperature, and the solution was stirred for 2 h. Sodium borohydride
(0.020 g, 0.42 mmol) was added in small portions over 5 min and the resulting
solution was stirred at ambient temperature for 48 h. Water (30 ml) was added and the
mixture was extracted with ethyl acetate (3 x 15 ml), and the combined organic layers
were washed with brine (2 x 15 ml), dried over MgSO4 and concentrated in vacuo.
The residue was dissolved in DMF (5 ml) under nitrogen, to which triethylamine
(0.050 ml, 0.35 mmol) was added. The solution was stirred at 70 oC for 24 h, poured
into water (50 ml) and extracted with ethyl acetate (3 x 20 ml). The combined organic
layers were washed with 10% citric acid solution (2 x 20 ml), water (4 x 20 ml), brine
(2 x 20 ml), dried over MgSO4 and concentrated in vacuo giving 10a as an oil
(0.092g, 99%). Rf 0.21, 40% ethyl acetate/hexane. IR (thin film)/cm-1 2986, 1682,
1388, 901. 1H NMR (two rotamers present)  5.81-5.66 (m, 1H, olefin CH), 5.26-5.16
(m, 2H, olefin CH2), 4.13-4.01 (m, 1H, allyl CH2), 3.85-3.67 (m, 1H, allyl CH2), 3.573.47 (m, 2H, pyrrolidine -CH2), 3.41-3.14 (m, 2H, lactam -CH2), 2.70-2.41 (m, 2H,
lactam -CH2), 2.12-1.80 (m, 4H, pyrrolidineand -CH2), 1.44 and 1.42 (2 x s,
9H, t-butyl). 13C NMR  174.24 and 174.20 (lactam carbonyl), 154.0 and 153.6 (Boc
carbonyl), 136.6 and 136.2 (olefin CH), 118.6, 117.9 (olefin CH2), 80.0 and 79.5 (tbutyl Cq), 67.0 and 66.7 (spiro Cq), 48.0 and 47.7 (allyl CH2), 46.1 (pyrrolidine CH2), 43.1 and 42.7 (lactam -CH2), 37.6 and 37.1 (lactam -CH2), 31.0 and 30.2
(pyrrolidine -CH2), 28.6 (t-butyl CH3), 23.4 and 22.7 (pyrrolidine-CH2).

Microanalysis: Found C, 57.81; H, 7.98; N, 8.60. Calculated for C15H24N2O3 (0.5
CHCl3): C, 57.76; H, 7.66; N, 8.69.
Method B: To a stirred solution of allylamine (0.37 ml, 4.9 mmol) in dry methanol (7
ml) was added a solution of 8 (1.20 g, 4.4 mmol) in dry methanol (1.5 ml).
Magnesium sulphate (0.316 g, 2.6 mmol) was added to the solution after 3 h and the
solution was then stirred for a further 2 h. The reaction was cooled to -4 oC and
NaBH4 (0.294 g, 7.8 mmol) was added portionwise. The reaction was quenched after
1 h with a saturated solution of NaHCO3 (5 ml) and water (5 ml). The mixture was
extracted with ethyl acetate (3 x 30 ml) then dried over MgSO4 and concentrated in
vacuo. The resulting oil was stirred at reflux temperature in toluene (15 ml) for 16 h.
After cooling to ambient temperature the solution was concentrated in vacuo giving
an oil which was purified on silica gel in 10% ethyl acetate/hexane to give a pale
yellow oil (0.685 g, 60%). For analysis see Method A.
7-Benzyl-6-oxo-1,7-diazaspiro[4.4]nonane-1-carboxylic acid tert-butyl ester
(10b) Method A: Prepared by a similar method to 10a (method A) using benzylamine
giving a pale yellow oil (88% yield). Rf 0.12, 40% ethyl acetate/hexane. IR (thin
film)/cm-1: 3000, 2950, 1700, 1680. 1H NMR (two rotamers present)  7.35-7.22 (m,
5H, aromatic), 4.90 (d, 1H, J = 14.7 Hz, benzyl CH2), 4.72 (d, 1H, J = 14.4 Hz,
benzyl CH2), 4.28 (d, 1H, J = 15 Hz, benzyl CH2), 3.97 (d, 1H, J = 14.5 Hz, benzyl
CH2), 3.62-3.42 (m, 2H, pyrrolidine -CH2), 3.34-3.03 (m, 2H, lactam -CH2), 2.662.39 (m, 1H, lactam -CH2), 2.21-2.08 (m, 1H, lactam -CH2), 2.06-1.95 (m, 2H,
pyrrolidine-CH2), 1.89-1.76 (m, 2H, pyrrolidine-CH2), 1.46 and 1.39 (2 x s, 9H, tbutyl).

13

C NMR (two rotamers present)  174.5 and 174.4 (lactam carbonyl), 153.5

and 153.4 (Boc carbonyl), 136.6 (ipso aromatic), 128.7, 128.4 and 128.3 (aromatic
CH), 80.0 and 79.5 (t-butyl Cq), 67.0 and 66.9 (spiro Cq), 48.0 and 47.8 (benzyl CH2),
47.5 and 47.4 (lactam -CH2), 42.9 and 42.7 (pyrrolidine -CH2), 37.8 and 37.1
(lactam -CH2), 30.9 and 30.8 (pyrrolidine -CH2), 28.5 (t-butyl CH3), 23.4 and 22.8
(pyrrolidine-CH2). Microanalysis: Found C, 62.55; H, 7.39; N, 7.14. Calculated for
C15H24N2O3 (0.5 CHCl3): C, 62.73; H, 7.42; N, 7.50.

Method B: 10b was prepared by a similar method to that used for 10a (Method B)
giving a pale yellow oil (1.46 g, 75%) after purification on silica gel in 15% ethyl
acetate/hexane. For analysis see method A.

(5S)

and

(5R)-6-Oxo-7-((1’R)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane-1-

carboxylic acid tert-butyl ester (12a and 12b).
To a stirred solution of (R)-(+)-1-phenylethyl amine (1.29 ml, 10.1 mmol) in dry
methanol (6 ml) was added a solution of aldehyde 8 (2.5 g, 9.22 mmol) in dry
methanol (2 ml). After 1 h of stirring at ambient temperature, magnesium sulphate
(0.66 g, 5.5 mmol) was added to the solution and stirring was continued for 4 h. The
reaction was cooled to –4 oC and NaBH4 (0.56 g, 15 mmol) was added portionwise
over 10 min. The reaction was quenched after 1 h at ambient temperature with a
saturated solution of NaHCO3 (7 ml) and water (3 ml). The aqueous layer was
extracted with ethyl acetate (3 x 30 ml), dried over MgSO4 and concentrated in vacuo
to give a yellow oil (2.10 g). The resulting oil was stirred at reflux temperature for 24
h in toluene (20 ml) in the presence of 50% sodium amide (suspension) in toluene
(0.20 ml, 5.2 mmol). After cooling to ambient temperature the solution was quenched
with H2O (4 ml), and extracted with ethyl acetate (3 x 20ml). The combined organics
were then concentrated in vacuo to give a colourless oil (0.909 g, 30%), which was
purified by flash column chromatography on silica gel in 10% ethyl acetate/hexane
resulting in 12a (0.491 g, 54%) as a white solid. Rf 0.78 (60% ethyl acetate/hexane).
Mp 92-96 oC. IR (KBr)/cm-1 3031, 2976, 1702, 1682, 1361. 1H NMR (two rotamers
present) δ 7.35-7.25 (m, 5H, aromatic), 5.77-5.49 (m, 1H, -CH), 3.58-3.44 (m, 2H,
pyrrolidine -CH2), 3.42-3.23 (m, 1H, lactam -CH2), 2.79-2.67 (m, 1H, lactam CH2), 2.61-2.37 (m, 1H, lactam -CH2), 2.13-1.66 (m, 5H, pyrrolidine - and -CH2,
and lactam -CH2), 1.58 and 1.56 (2 x d, 3H, J = 9.87 Hz, -CH3), 1.48 and 1.46 (2 x
s, 9H, t-butyl CH3).

13

C NMR δ (two rotamers present) 174.1 (C=O, lactam), 153.5

(C=O, Boc), 140.4 (ipso aromatic), 128.4 (meta), 127.6 (ortho), 127.1 (para), 80.0
and 79.4 (t-butyl Cq), 67.3 (spiro Cq), 49.6 and 49.2 (-CH), 48.1 and 47.8
(pyrrolidine -CH2), 38.6 and 37.9 (CH2, lactam -CH2), 36.9 and 36.6 (CH2,
pyrrolidine -CH2), 30.4 and 29.9 (lactam -CH2), 28.5 and 28.4 (t-butyl CH3), 23.3
and 22.4 (CH2, pyrrolidine -CH2), 15.6 and 15.5 (-CH3). Microanalysis: Found C,
69.87; H, 8.49; N, 7.86. Calculated for C20H28N2O3: C, 69.74; H, 8.16; N, 8.13.

12b was obtained as a white solid. Rf 0.68 (60% ethyl acetate/hexane). Mp 128-132
o

C. IR (KBr)/cm-1 3032, 2975, 1700, 1685, 1360. 1H NMR (two rotamers present) δ

7.45-7.22 (m, 5H, aromatic), 5.48 (q, 0.5H, J = 7.14 Hz, -CH), 5.38 (q, 0.5H, J =
7.14 Hz, -CH), 3.61-3.48 (m, 2H, pyrrolidine -CH2), 3.19-3.03 (m, 2H, lactam CH2), 2.58-2.37 (2x m, 1H, lactam -CH2), 2.17-1.76 (m, 5H, pyrrolidine - and CH2, and lactam -CH2), 1.50 and 1.48 (2 x d, 3H, J = 14.28 Hz, -CH3), 1.46 and
1.26 (2 x s, 9H, t-butyl CH3).

13

C NMR (two rotamers present) δ 174.4 and 174.2

(C=O, lactam), 153.5 (C=O, Boc), 140.1 (ipso aromatic), 127.64 (meta), 127.61
(ortho), 127.5 (para), 80.3 and 79.5 (spiro Cq), 67.5 and 67.4 (t-butyl Cq), 50.9 and
49.5 (-CH), 48.6 and 48.2 (CH2, pyrrolidine -CH2), 38.9 and 38.7 (CH2, lactam CH2), 37.5 and 37.1 (CH2, pyrrolidine -CH2), 30.4 and 30.1 (CH2, lactam -CH2),
28.8 and 28.5 (CH3, (t-butyl CH3), 23.6 and 22.6 (CH2, pyrrolidine -CH2), 16.6 and
16.4 (CH3, (-CH3). Microanalysis: Found C, 70.38; H, 8.65; N, 7.53. Calculated for
C20H28N2O3: C, 69.74; H, 8.16; N, 8.13.

(5R)

and

(5S)-6-Oxo-7-((1’S)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane-1-

carboxylic acid tert-butyl ester (12c and 12d).
Prepared by a similar method to the preparation of 12a and 12b using (S)-(-)-1phenylethyl amine in 51% yield. 12c was obtained as a white solid. Analytical data
were the same as 12b. Microanalysis: Found C, 69.68; H, 8.14; N, 8.05. Calculated
for C20H28N2O3: C, 69.74; H, 8.16; N, 8.13.
12d was obtained as a white solid. Analytical data were the same as 12a.
Microanalysis: Found C, 69.49; H, 8.14; N, 7.89. Calculated for C20H28N2O3: C,
69.74; H, 8.16; N, 8.13.
(5S)-6-Oxo-7-((1’R)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane (13a).
To a stirred solution of 12a (0.270 g, 0.78 mmol) in DCM (2.7 ml) was added TFA
(2.7 ml) and the resulting solution was stirred for 2 h at ambient temperature. The
solution was basified to pH 10 with aqueous 3 M KOH solution, and extracted with
chloroform (2 x 30 ml). The combined organic layers were washed with brine (2 x 20
ml), dried over MgSO4 and concentrated in vacuo giving a yellow oil (0.169 g, 89%).
Rf 0.24 (10% methanol/ethyl acetate). [α] 20
D +9616.6 (c = 0.0180, methanol). IR (thin

film)/cm-1 3329, 2972, 2876, 1682. 1H NMR  7.36-7.26 (m, 5H, aromatic), 5.50-5.46
(q, 1H, J = 6.93 Hz, -CH), 3.29-3.20 (m, 2H, pyrrolidine -CH2), 2.98-2.90 and
2.84-2.76 (m x 2, 2H, lactam -CH2), 2.06 (s (br.), 1H, N-H), 2.01-1.74 (m, 6H,
pyrrolidine - and -CH2, and lactam -CH2), 1.55 (d, 3H, J = 7.14 Hz, -CH3). 13C
NMR  176.74 (C=O, lactam), 140.0 (ipso aromatic), 128.5 (meta), 127.5 (ortho),
126.9 (para), 67.9 (spiro Cq), 49.4 (-CH), 47.5 (lactam -CH2), 39.0 (pyrrolidine CH2), 35.2 (CH2, pyrrolidine -CH2), 34.8 (lactam -CH2), 26.1 (pyrrolidine -CH2),
16.0 (-CH3).

(5R)-6-Oxo-7-((1’R)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane (13b).
This was prepared from 12b, by the method used for 12a. 73% yield as a light yellow
o
oil. Rf 0.26 (10% methanol/ethyl acetate). [α] 20
D +13211.3 (c = 0.0246, methanol).

IR (thin film)/cm-1 3484, 2970, 2876, 1682. 1H NMR  7.36-7.26 (m, 5H, aromatic),
5.46-5.39 (q, 1H, J = 7.14 Hz, -CH), 3.34-3.15 (m, 2H, pyrrolidine -CH2), 3.082.94 (m x 2, 2H, lactam -CH2), 2.77 (s (br.), 1H, N-H), 2.04-1.73 (m, 6H, pyrrolidine

- and -CH2, and lactam -CH2), 1.55 (d, 3H, J = 7.14 Hz, -CH3). 13C NMR 
175.9 (C=O, lactam), 139.0 (ipso aromatic), 128.6 (meta), 127.5 (ortho), 126.9
(para), 68.1 (spiro Cq), 49.6 (CH, -CH), 47.2 (lactam -CH2), 39.1 (pyrrolidine CH2), 35.1 (pyrrolidine -CH2), 34.2 (lactam -CH2), 25.7 (CH2, pyrrolidine -CH2),
16.3 (CH3, -CH3).

(5R)-6-Oxo-7-((1’S)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane (13c).
This was prepared from 12c, by the method used for 12a. 76% yield as a light yellow
oil. Analytical data were the same as 13a.

(5S)-6-Oxo-7-((1’S)-phenylethyl-)-1,7-diaza-spiro[4.4]nonane (13d).
This was prepared from 12d, by the method used for 13a. 80% yield as a light yellow
oil. Analytical data were the same as 13b.

(5S)-7-((1’R)-Phenylethyl-)-1,7-diaza-spiro[4.4]nonane (14a).
To a stirring solution of lithium aluminium hydride 1 M solution in THF (14.8 ml,
14.8 mmol) in dry THF (5ml) at -20 oC under nitrogen, was added a 13a (0.179 g,

0.74 mmol) in dry THF (1 ml) and the solution was allowed to warm to ambient
temperature and stirred for 48 h. To the reaction mixture, saturated sodium chloride
solution and 50% sodium hydroxide solution were added alternately (each time
adding 3 drops), until no hydride was left (i.e. until the solution did not vigorously
react). The solution was then filtered, washing the precipitate thoroughly with
chloroform (3 x 20ml). The combined washings were dried over K2CO3 and
concentrated in vacuo giving a yellow oil, which was purified on preparative TLC on
silica gel in 40% methanol/chloroform to give a pale yellow oil (0.090 g, 53%). Rf
0.12 (40% methanol/chloroform). [α] 20
D +4736.8 (c = 0.019, methanol). IR (thin
film)/cm-1 3354, 2970, 2776. [Note: Pyrrolidine ring derived from lactam is labelled
pyrrolidine B and other is pyrrolidine A] 1H NMR  7.34-7.21 (m, 5H, aromatic), 3.24
(q, 1H, J = 6.6 Hz, -CH), 3.01-2.88 (m, 3H, pyrrolidine B -CH2 and pyrrolidine A

-CH2), 2.62-2.54 (m, 2H, pyrrolidine B -CH2 and pyrrolidine B -CH2), 2.37 (d,
1H, J = 9.33 Hz, pyrrolidine B -CH2), 1.89-1.68 (m, 6H, pyrrolidine B -CH2,
pyrrolidine A -CH2 and pyrrolidine A -CH2), 1.35 (d, 3H, J = 6.6 Hz, -CH3). 13C
NMR  145.43 (ipso aromatic), 128.2 (meta), 127.0 (ortho), 126.7 (para), 68.21
(spiro Cq), 65.5 (-CH), 64.8 (pyrrolidine B -CH2), 52.0 (pyrrolidine B -CH2), 45.2
(pyrrolidine A -CH2), 38.2 (pyrrolidine A -CH2), 37.8 (pyrrolidine B -CH2), 24.7
(pyrrolidine A -CH2), 23.6 (CH3, -CH3). Mass spectrum m/z [M+H] 231.1857
(calculated for C15H23N2 231.1861).

(5R)-7-((1’R)-Phenylethyl-)-1,7-diaza-spiro[4.4]nonane (14b).
This was prepared from 13b, by the method used for 14a. 46% yield as a pale yellow
oil. Rf 0.12 (40% methanol/chloroform). [α] 20
D +3928.5 (c = 0.021, methanol). IR
(thin film)/cm-1 3359, 2970, 2776. 1H NMR  7.35-7.21 (m, 5H, aromatic), 3.27 (q,
1H, J = 6.6 Hz, -CH), 3.03-2.84 (m, 3H, pyrrolidineB -CH2 and pyrrolidineA CH2), 2.52 (d, 1H, J = 9.5 Hz, pyrrolidineB -CH2), 2.40 (d, 1H, J = 9.5 Hz,
pyrrolidineB -CH2), 2.4-2.36 (m, 1H, pyrrolidineB -CH2), 1.94-1.74 (m, 6H,
pyrrolidineB -CH2, pyrrolidineA -CH2 and pyrrolidineA -CH2), 1.35 (d, 3H, J =
6.6 Hz, -CH3).

13

C NMR  145.35 (ipso aromatic), 128.2 (meta), 127.1 (ortho),

126.7 (para), 68.4 (spiro Cq), 65.3 (-CH), 64.3 (pyrrolidineB -CH2), 51.7
(pyrrolidineB -CH2), 45.0 (pyrrolidineA -CH2), 37.9 (pyrrolidineA -CH2), 37.1

(pyrrolidineB -CH2), 24.3 (pyrrolidineA -CH2), 22.8 (-CH3). Mass spectrum m/z
[M+H] 231.1858 (calculated for C15H23N2 231.1861).

(5R)-7-((1’S)-Phenylethyl-)-1,7-diaza-spiro[4.4]nonane (14c).
This was prepared from 13c, by the method used for 14a. 48% yield as a pale yellow
oil. Analytical data were the same as 14a. Mass spectrum m/z [M+H] 231.1864
(calculated for C15H23N2 231.1861).

(5S)-7-((1’S)-Phenylethyl-)-1,7-diaza-spiro[4.4]nonane (14d).
This was prepared from 13d, by the method used for 14a. 43% yield as a pale yellow
oil. Analytical data was the same as 14b. Mass spectrum m/z [M+H] 231.1871
(calculated for C15H23N2 231.1861).
X-Ray Crystallography:
Suitable crystals of 15a and 15b for X-ray study were obtained from ethanol
solutions. The data were collected at 150(2)K on a Bruker APEX CCD diffractometer.
The structure was solved by direct methods and refined on F2 using all the
reflections.19 All the non-hydrogen atoms were refined using anisotropic atomic
displacement parameters and hydrogen atoms were inserted at calculated positions
using a riding model.

Compound 15a. Crystal data: C15H22Cl2N2Zn, M = 366.62, triclinic, a = 7.288(3), b
= 10.862(5), c = 11.169(5) Å,  = 90.304(6)°,  = 103.671(5)°,  = 95.005(6)°, U =
855.5(7) Å3, space group P1, Z = 2, μ(Mo-Kα) = 1.740 mm-1. 6662 data (5905
unique, Rint = 0.0261) were measured in the range 1.88 < θ < 25.99˚. R1(I > 2σ(I)) =
0.0376 and wR2(all data) = 0.0986. Goodness of fit on F2 = 1.004. CCDC No. 641381.
Molecular Modelling:
The energy of the conformations of 12a and 12b were minimised using the MM+
molecular mechanics force field in HYPERCHEM 7.5.
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Captions

Figure 1. Ethylenediamine 1; trans-1,2-Diaminocyclohexane 2; (-)-Sparteine 3 and
1,7-Diaza-spiro[4.5]decane 4.
Figure 2: Cyclisation methods for proline-derived spirolactams.8,10,11
Figure 3. Energy minimised conformations of 12a (S,R) and 12b (R,R).17

Figure 4. X-ray crystal structure of spirodiamine-ZnCl2 complex 15a.
Figure 5. Mukaiyama’s diamines 16, complexed to Sn(OTf)217 and ZnCl2.
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Figure 1. Ethylenediamine 1; trans-1,2-Diaminocyclohexane 2; (-)-Sparteine 3 and
1,7-Diaza-spiro[4.5]decane 4.
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Figure 4. X-ray crystal structure of spirodiamine-ZnCl2 complex 15a.
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Tables

Table 1. Selected bond lengths (Å) and angles (º) for 15a.

Bond

Bond lengths

Angle

Bond Angles

Zn(1A)-N(1A)

2.067(5)

N(1A)-Zn(1A)-N(2A)

84.4(2)

Zn(1A)-N(2A)

2.104 6)

N(1A)-Zn(1A)-Cl(1A)

113.11(16)

Zn(1A)-Cl(1A)

2.213(2)

N(2A)-Zn(1A)-Cl(1A)

117.00(16)

Zn(1A)-Cl(2A)

2.2191(18)

N(1A)-Zn(1A)-Cl(2A)

108.42(17)

Zn(1B)-N(1B)

2.049(5)

N(2A)-Zn(1A)-Cl(2A)

107.20(16)

Zn(1B)-N(2B)

2.117(5)

Cl(1A)-Zn(1A)-Cl(2A)

120.71(7)

Zn(1B)-Cl(2B)

2.2118(19)

N(1B)-Zn(1B)-N(2B)

84.4(2)

Zn(1B)-Cl(1B)

2.213(2)

N(1B)-Zn(1B)-Cl(2B)

109.46(16)

N(2B)-Zn(1B)-Cl(2B)

111.39(17)

N(1B)-Zn(1B)-Cl(1B)

110.69(17)

N(2B)-Zn(1B)-Cl(1B)

116.31(17)

Cl(2B)-Zn(1B)-Cl(1B)

119.11(7)

